Founder and Chairman of the Scientific Advisory Board
Prof. Jackson’s research and discoveries in protein ubiquitylation and deubiquitylation led to the founding of Mission to explore new therapeutic opportunities across various disease areas.
He is Professor of Biology at the University of Cambridge and Head of Cancer Research UK Laboratories at the Gurdon Institute, Cambridge. As a pioneer in the field of DNA repair and DNA-damage signalling, Prof. Jackson’s research has shaped our understanding of cellular responses to DNA damage and of how defects in these responses contribute to disease. Prof. Jackson founded KuDOS Pharma that was acquired by AstraZeneca in 2006. Olaparib, which was developed by KuDOS, was approved for advanced BRCA+ ovarian cancer in USA and Europe in 2014.
Prof. Jackson carried out his post-doctoral training in the lab of Professor Robert Tjian at Berkeley, USA. He obtained his BSc in Biochemistry from Leeds University, UK and his PhD from Edinburgh University. He is a fellow of both the Royal Society and the UK Academy of Medical Sciences.